Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) have been given an average rating of “Moderate Buy” by the eight analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $35.71.

DAWN has been the subject of a number of recent analyst reports. Wedbush reissued an “outperform” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, July 25th. Bank of America raised Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and boosted their target price for the stock from $11.00 to $24.00 in a research report on Thursday, August 1st. Piper Sandler reissued an “overweight” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. Needham & Company LLC reissued a “buy” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday. Finally, JPMorgan Chase & Co. reduced their price target on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th.

Insider Activity

In other news, insider Samuel C. Blackman sold 2,232 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $14.00, for a total transaction of $31,248.00. Following the completion of the sale, the insider now owns 1,127,535 shares of the company’s stock, valued at $15,785,490. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, General Counsel Adam Dubow sold 3,202 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $14.00, for a total transaction of $44,828.00. Following the completion of the transaction, the general counsel now directly owns 26,928 shares in the company, valued at approximately $376,992. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Samuel C. Blackman sold 2,232 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $14.00, for a total value of $31,248.00. Following the transaction, the insider now owns 1,127,535 shares of the company’s stock, valued at approximately $15,785,490. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 48,748 shares of company stock valued at $689,072 in the last quarter. 8.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in DAWN. ProShare Advisors LLC grew its holdings in Day One Biopharmaceuticals by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 17,379 shares of the company’s stock valued at $287,000 after buying an additional 1,447 shares in the last quarter. Summit Rock Advisors LP purchased a new stake in Day One Biopharmaceuticals during the 1st quarter valued at approximately $851,000. Altitude Crest Partners Inc. purchased a new stake in Day One Biopharmaceuticals during the 1st quarter valued at approximately $3,230,000. Estuary Capital Management LP grew its holdings in Day One Biopharmaceuticals by 82.5% during the 1st quarter. Estuary Capital Management LP now owns 1,611,137 shares of the company’s stock valued at $26,616,000 after buying an additional 728,240 shares in the last quarter. Finally, Bayesian Capital Management LP purchased a new stake in Day One Biopharmaceuticals during the 1st quarter valued at approximately $221,000. 87.95% of the stock is currently owned by institutional investors.

Day One Biopharmaceuticals Price Performance

Shares of Day One Biopharmaceuticals stock opened at $14.65 on Friday. The stock has a market cap of $1.29 billion, a price-to-earnings ratio of -14.22 and a beta of -1.51. The firm’s 50-day moving average is $14.19 and its 200 day moving average is $14.39. Day One Biopharmaceuticals has a 1 year low of $10.90 and a 1 year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.58. The business had revenue of $93.76 million during the quarter, compared to analysts’ expectations of $15.05 million. During the same period last year, the firm posted ($0.54) EPS. On average, equities analysts expect that Day One Biopharmaceuticals will post -1.65 EPS for the current fiscal year.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.